Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy

Domvri, Kalliopi; Zarogoulidis, Paul; Darwiche, Kaid; Browning, Robert; Li, Qiang; Turner, J. Francis; Kioumis, Ioannis; Spyratos, Dionysios; Porpodis, Κonstantinos; Papaiwannou, Antonis; Tsiouda, Theodora; Freitag, Lutz; Zarogoulidis, Konstantinos

doi:10.7150/jca.7734

Cited by 74 publications

(76 citation statements)

References 218 publications

(237 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Despite improvements in surgery, radiotherapy and chemotherapy, the overall 5-year survival rate remains poor, at <15% (1,3). As the deregulation of oncogenes or tumor suppressors has been implicated in the development and progression of NSCLC, investigations regarding the molecular targets show promise for the treatment of NSCLC (4,5).…”

Section: Introductionmentioning

confidence: 99%

MicroRNA-133b inhibits the migration and invasion of non small cell lung cancer cells via targeting FSCN1

et al. 2016

View full text Add to dashboard Cite

Abstract. MicroRNA (miR)-133b has been reported to act as a tumor suppressor in multiple types of human cancers, including non small cell lung cancer (NSCLC). However, the underlying mechanism by which miR-133b inhibits NSCLC metastasis remains largely unclear. In the present study, reverse transcription-quantitative polymerase chain reaction and western blotting were used to detect messenger RNA and protein expression. A wound healing assay and transwell assay were used to examine the cell migration and invasion. The expression level of miR-133b was found to be significantly downregulated in NSCLC cell lines compared with normal lung epithelial BEAS-2B cells. Further investigation identified fascin1 (FSCN1) as a direct target of miR-133b in NSCLC cells. The expression of FSCN1 was significantly increased in NSCLC cell lines compared with BEAS-2B cells, and its protein expression was negatively regulated by miR-133b in NSCLC A549 cells. Further investigation showed that the upregulation of miR-133b notably inhibited NSCLC cell migration and invasion, while the overexpression of FSCN1 significantly promoted NSCLC cell migration and invasion. Furthermore, the overexpression of FSCN1 reversed the suppressive effect of miR-133b overexpression on NSCLC cell migration and invasion. Accordingly, the present study suggests that miR-133b inhibits the migration and invasion of NSCLC cells via directly targeting FSCN1, and thus may be used for the treatment of NSCLC metastasis.

show abstract

Section: Introductionmentioning

confidence: 99%

MicroRNA-133b inhibits the migration and invasion of non small cell lung cancer cells via targeting FSCN1

et al. 2016

View full text Add to dashboard Cite

show abstract

“…In the past 5 years, novel targeted therapies with tyrosine kinase inhibitors based on the epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), proto-oncogene B-Raf and v-Raf murine sarcoma viral oncogene homolog B (BRAF) and proto-oncogene tyrosine-protein kinase ROS-1 (ROS-1) are used for treatment in non-small cell lung cancer (NSCLC) patients (3). Immunotherapy in the past two years brought is considered a breakthrough NSCLC (4).…”

mentioning

confidence: 99%

Nivolumab as first-line treatment in non-small cell lung cancer patients—key factors: tumor mutation burden and PD-L1 ≥50%

Papadopoulos¹,

Maragouli²,

Papatsibas³

et al. 2018

Transl. Lung Cancer Res.

Self Cite

View full text Add to dashboard Cite

“…[15,16] Unfortunately disease relapse occurs and treatment has to change. In the case of erlotinib the anti-vascular endothelial growth factor (VEGF) bevasizumab can be added in order to enhance the already administered treatment.…”

Section: Tyrosine Kinase Inhibitorsmentioning

confidence: 99%

First and Best Treatments for EGFR and PD-L1 - Competition for First Line Therapy in Adenocarcinoma

Man¹,

Hohenforst-Schmidt²,

Yarmus³

et al. 2017

Oncomedicine

Self Cite

View full text Add to dashboard Cite

Lung cancer is still diagnosed at advanced stages since there are no blood markers or efficient prevention programs. Moreover, lack of early disease symptoms do lead patients for early diagnosis. In the past ten years novel targeted and non-targeted therapies have entered the market for advanced stage disease patients. Epidermal growth factor receptor and anaplastic lymphoma kinase agents are considered an excellent choice as first line treatment for adenocarcinoma. However; in the past few months PD-L1 >50% patients can be treated with immunotherapy as first line treatment. Moreover; second generation tyrosine kinase inhibitors are already on the market in the case of disease relapse in EGFR and ALK positive patients. In the current mini review we will focus on current up-to-date data regarding the best choice between tkis and immunotherapy as first line treatment for adenocarcinoma.

show abstract

Molecular Targeted Drugs and Biomarkers in NSCLC, the Evolving Role of Individualized Therapy

Cited by 74 publications

References 218 publications

MicroRNA-133b inhibits the migration and invasion of non small cell lung cancer cells via targeting FSCN1

MicroRNA-133b inhibits the migration and invasion of non small cell lung cancer cells via targeting FSCN1

Nivolumab as first-line treatment in non-small cell lung cancer patients—key factors: tumor mutation burden and PD-L1 ≥50%

First and Best Treatments for EGFR and PD-L1 - Competition for First Line Therapy in Adenocarcinoma

Contact Info

Product

Resources

About